Re:Search Institution Members

85 Results for Members

Members

UCB research institutions, including the Henry Wheeler Center for Emerging and Neglected Diseases, provide a...

The University of California, San Diego (UCSD) is a research-focused public institution, with numerous...

UCSF focuses on conducting both basic and translational research, and played a key role in the development of...

UGA's Center for Tropical & Emerging Global Diseases (CTEGD) is built on a strong foundation in parasitology,...

The University is one of the largest recipients of federal government research grants in the country, and...

The University of South Florida is a high-impact, global research university. Faculty members in its...

122 Results for Collaborations

Collaborations

Dr. Siqueira-Neto was interested in screening phosphodiesterase (PDE) V inhibitors for activity against kinetoplastids and schistosomes, as one compound of this class showed activity against a Trypanosoma cruzi PDE involved in osmoregulation. BVGH connected Dr. Siqueira-Neto with Eisai, which provided a select set of PDEV inhibitors for Dr. Siqueira-Neto to screen in cell-based and enzyme-based assays against Trypanosoma, Brugia, Leishmania, and Schistosoma.

Dr. Keiser, Head of the Helminth Drug Development Unit at Swiss TPH, maintains in vitro and in vivo assays for a wide range of helminth life cycles. BVGH reviewed a publication detailing the effect of nicotinic acetylcholine receptor (nAChR) agonists on rat hookworm, and contacted Dr. Keiser to gauge her interested in screening related compounds. Dr. Keiser expressed interest, and Pfizer provided seven nAChR agonists that Dr. Keiser screened in her assays against Necator americanus, Ancylostoma ceylanicum, and Heligmosomoides polygyrus.

Soil-transmitted helminthiases, caused by multiple species of parasitic worms, affect more than 1.5 billion people, or nearly 25% of the world’s population. Dr. Keiser, Head of the Helminth Drug Development Unit at Swiss TPH, maintains in vitro and in vivo assays for a wide range of helminth life cycles. As part of its commitment to advancing global public health and accelerating discovery of new treatments for neglected diseases, J&J shared JNJ-46336173, a nicotinic acetylcholine receptor (nAChR) agonist, and over 100 analogs thereof, with Dr. Keiser through WIPO Re:Search. Dr. Keiser screened these compounds for activity against three parasitic helminth species.

Phosphodiesterases (PDEs) are important regulators of cell signal transduction, and PDE inhibitors have been developed to treat various diseases, such as erectile dysfunction and chronic obstructive pulmonary disease (COPD). After reading reports that PDE inhibition in T. brucei, which causes HAT, led to parasite death, Dr. Pollastri and colleagues screened existing human PDE inhibitors for activity against T. brucei PDEs. When the team examined the inhibitors’ structure-activity relationships (SAR) — correlations between compound structures and activity against parasite PDEs —, it was difficult to discern clear trends or patterns, which slowed the compound optimization process significantly. BVGH connected Dr. Pollastri with scientists at Eisai who had experience working with PDE inhibitors. The scientists provided Dr. Pollastri with valuable advice on compound optimization, including suggestions for future approaches and experiments.

Resistance to current antimalarial drugs is a serious problem. New therapeutics with novel mechanisms of action are needed to curtail the suffering caused by malaria. Preliminary data from Dr. Gilbert and others suggested that a certain class of compounds might have antimalarial properties. Eisai shared proprietary compounds of that class with Dr. Gilbert to screen for activity against Malaria parasites.

Resistance to current antimalarial drugs is a serious problem. There is a critical need for new medications with novel mechanisms of action. Preliminary data from Dr. Gilbert and others suggested that a certain class of compounds might have antimalarial activity. BVGH connected Dr. Gilbert with scientists at Eisai, who shared proprietary compounds of that class for Dr. Gilbert’s malaria drug discovery program.

127 Results for Assets

Assets

At the National Institute of Parasitic Diseases (NIPD), Dr. Jun-Hu Chen and others have developed a protein microarray that can be used for identifying bio-markers for potential use in malarial parasite diagnostics and vaccine development.
Dr. Xue-nian Xu’s group at the National Institute of Parasitic Diseases has developed the Cs1 rapid diagnostic immunochromatographic test strip for screening to find human patients infected with Chloriorciasis (Chinese liver fluke). Chinese liver fluke parasites reside in undercooked, smoked pickled and salted freshwater fish and infect humans who eat the fish. Dr Xu’s group is also developing a kit for the direct detection of the antigen of Chinese liver fluke. This kit might be able to detect liver fluke in uncooked fish. Dr. Xu is interested in collaborating with groups around these liver fluke diagnostic tests.
The University of Buea has experience of investigating crude plant extracts for selective activity in the search for novel filaricides.
The University of Buea is willing to enter into partnerships for access to its state of the art facilities and expertise in drug screening for onchocerciasis (whole parasite: adult worms, microfilariae and L3; medium throughput). The screens are primarily based on the Onchocerca ochengi model and include a Loa loa microfilariae screening component.
The University of Buea has access to onchocerciasis patients, and can therefore provide to partners a range of biological materials including serum and parasites. We can also undertake epidemiological surveys and field testing. The University of Buea is willing to enter into partnerships for access to its state of the art facilities and expertise in drug screening for onchocerciasis whole parasite: adult worms, microfilariae and L3; medium throughput . The screens are primarily based on the Onchocerca ochengi model and include a Loa loa microfilariae screening component.
The schistosome biological supply center at TBRI makes available to researchers a wide range of schistosome biological material (alive, fresh, frozen and as antigens) for testing antischistosomal compounds. This center supplies biological material to TBRI researchers and to > 20 international research institutes.